Genetic Technology News

摘要

Vistagen Develops Epilepsy Drug; New Gene for CNS Therapy at Neurologix; Geron Starts Telomerase Inhibitor CCL Clinical; deCODE's Asthma Drug; GTN Strategic Partners; Some Important Patents for You To Check; GTN Market Forecast: New Brain Cancer Therapies. GENENTECH AGENT IMPROVES VISION OF AMD PATIENTS. Wet age-related macular degeneration (AMD) is a major cause of blindness. It is caused by growth of new blood vessels in the macular region of the retina in the eye. The potential market for effective new therapies is huge (GTN 1/3/03). One new product that slows vision loss is already on the market. Now preliminary analysis of results of a phase III clinical trial of Lucentis (ranibizumab), being developed by Genentech Inc. shows that it does more. It significantly improved vision in AMD patients.